Robert W Gao1, Daniel J Weisdorf2, Todd E DeFor3, Eric Ehler4, Kathryn E Dusenbery5. 1. Medical School, University of Minnesota, Minneapolis, Minnesota. 2. Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota. 3. Biostatistics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. 4. Department of Radiation Oncology, University of Minnesota, Minneapolis, Minnesota. 5. Department of Radiation Oncology, University of Minnesota, Minneapolis, Minnesota. Electronic address: dusen001@umn.edu.
Abstract
PURPOSE: To determine the relationship between dose rate and other factors in the development of idiopathic pneumonia syndrome (IPS) in patients with acute lymphoblastic leukemia or acute myeloid leukemia who are undergoing total body irradiation (TBI)-based myeloablative conditioning for allogeneic hematopoietic cell transplantation (HCT). METHODS AND MATERIALS: From 2006 to 2016, 202 patients with acute leukemia (111 acute lymphoblastic leukemia, 91 acute myeloid leukemia) ranging in age from 1 to 57 years (median, 25 years) underwent allogeneic HCT at University of Minnesota. Pretransplantation conditioning included cyclophosphamide (120 mg/kg) with (68%) or without fludarabine (75 mg/m2) followed by 13.2 Gy TBI given in 8 twice-daily fractions of 1.65 Gy over 4 days. Dose rate varied based on linear accelerator availability and ranged from 8.7 to 19.2 cGy/min. Patients were stratified by receipt of high-dose-rate (HDR; >15 cGy/min; 56%) or low-dose-rate (LDR; ≤15 cGy/min; 44%) TBI for all 8 fractions. IPS was defined as pulmonary injury based on clinical symptoms, radiographic evidence, or pulmonary function testing within 100 days of HCT in the absence of concurrent infection. RESULTS: IPS developed in 42 patients (21%) between 4 and 73 days (median, 16 days) after transplantation. HDR TBI was associated with a higher rate of IPS compared with LDR TBI (29% vs 10%; P < .01). On multiple regression analysis, HDR remained a significant predictor of IPS (hazard ratio, 2.6; 95% confidence interval, 1.2-5.3; P = .01), and this led to inferior 1-year overall survival (60% vs 76%; P = .01) and increased 1-year nonrelapse mortality (28% vs 15%; P = .02). CONCLUSIONS: TBI dose rates ≤15 cGy/min reduce the risk of posttransplantation IPS and improve overall survival. LDR TBI should be strongly considered as an easily implemented parameter to improve the safety of pretransplantation TBI-based conditioning.
PURPOSE: To determine the relationship between dose rate and other factors in the development of idiopathic pneumonia syndrome (IPS) in patients with acute lymphoblastic leukemia or acute myeloid leukemia who are undergoing total body irradiation (TBI)-based myeloablative conditioning for allogeneic hematopoietic cell transplantation (HCT). METHODS AND MATERIALS: From 2006 to 2016, 202 patients with acute leukemia (111 acute lymphoblastic leukemia, 91 acute myeloid leukemia) ranging in age from 1 to 57 years (median, 25 years) underwent allogeneic HCT at University of Minnesota. Pretransplantation conditioning included cyclophosphamide (120 mg/kg) with (68%) or without fludarabine (75 mg/m2) followed by 13.2 Gy TBI given in 8 twice-daily fractions of 1.65 Gy over 4 days. Dose rate varied based on linear accelerator availability and ranged from 8.7 to 19.2 cGy/min. Patients were stratified by receipt of high-dose-rate (HDR; >15 cGy/min; 56%) or low-dose-rate (LDR; ≤15 cGy/min; 44%) TBI for all 8 fractions. IPS was defined as pulmonary injury based on clinical symptoms, radiographic evidence, or pulmonary function testing within 100 days of HCT in the absence of concurrent infection. RESULTS:IPS developed in 42 patients (21%) between 4 and 73 days (median, 16 days) after transplantation. HDR TBI was associated with a higher rate of IPS compared with LDR TBI (29% vs 10%; P < .01). On multiple regression analysis, HDR remained a significant predictor of IPS (hazard ratio, 2.6; 95% confidence interval, 1.2-5.3; P = .01), and this led to inferior 1-year overall survival (60% vs 76%; P = .01) and increased 1-year nonrelapse mortality (28% vs 15%; P = .02). CONCLUSIONS: TBI dose rates ≤15 cGy/min reduce the risk of posttransplantation IPS and improve overall survival. LDR TBI should be strongly considered as an easily implemented parameter to improve the safety of pretransplantation TBI-based conditioning.
Authors: Darren Zuro; Stefano Vagge; Sara Broggi; Stefano Agostinelli; Yutaka Takahashi; Jamison Brooks; Paulina Leszcynska; An Liu; Claudio Zucchetti; Simonetta Saldi; Chunhui Han; Mauro Cattaneo; Sebastian Giebel; Marc Andre Mahe; James F Sanchez; Parham Alaei; Chiara Anna; Kathryn Dusenbery; Antonio Pierini; Guy Storme; Cynthia Aristei; Jeffrey Y C Wong; Susanta Hui Journal: Radiother Oncol Date: 2019-08-14 Impact factor: 6.280
Authors: David H Thomas; Brian Miller; Rachel Rabinovitch; Sarah Milgrom; Brian Kavanagh; Quentin Diot; Moyed Miften; Leah K Schubert Journal: J Appl Clin Med Phys Date: 2020-05-19 Impact factor: 2.102
Authors: Jose R Teruel; Sameer Taneja; Paulina E Galavis; K Sunshine Osterman; Allison McCarthy; Martha Malin; Naamit K Gerber; Christine Hitchen; David L Barbee Journal: J Appl Clin Med Phys Date: 2021-02-10 Impact factor: 2.102
Authors: Michael Oertel; Jonas Martel; Jan-Henrik Mikesch; Sergiu Scobioala; Christian Reicherts; Kai Kröger; Georg Lenz; Matthias Stelljes; Hans Theodor Eich Journal: Cancers (Basel) Date: 2021-11-11 Impact factor: 6.639
Authors: Bianca A W Hoeben; Jeffrey Y C Wong; Lotte S Fog; Christoph Losert; Andrea R Filippi; Søren M Bentzen; Adriana Balduzzi; Lena Specht Journal: Front Pediatr Date: 2021-12-03 Impact factor: 3.418
Authors: Michael Oertel; Christopher Kittel; Jonas Martel; Jan-Henrik Mikesch; Marco Glashoerster; Matthias Stelljes; Hans Theodor Eich Journal: Cancers (Basel) Date: 2021-06-12 Impact factor: 6.639